Ophthalmolgy worldwide: Data and Numbers

EMR Implementation Research US 2014:

  • For ophthalmology practices that have already implemented EMR, the goal of this research is to discover the satisfaction level with key EMR attributes.
  • For practices that have not yet implemented EMR, the goal is to discover the concerns that have caused the delay in moving forward with EMR implementation.
  • This is a directional study that will provide insight to the marketplace, attitudes toward system attributes, and provide guidance to continued market research.
  • This research project was conducted with a restricted grant from ifa systems, AG.


The international ophthalmology is a growing medical “business” with a wide range of successful therapies and treatments and growing market volumes:

- Worldwide approx. 178.000 ophthalmologists (MDs) and 32.000 optometrists (ODs) provide eye care services:

  • Europe 34.000 MDs/9.000 ODs
  • USA/Canada 21.500 MDs/18.000 ODs
  • Latin America 38.000 MDs
  • China 31.000
  • India 29.500
  • Other regions 24.000 MDs/5.000 ODs

- The total (fee) revenue of all ophthalmologists in 2016 is estimated with approx. 88,0 B US$ (optometrists  9,0 B US$.

- Based on historical data and up to date market research the revenue volume is expected to increase yearly by 4,0%. Retinal treatments and therapies can become the most important market factors within the next  decade.

- The most important eye diseases worldwide (cause for blindness according to WHO):

  • Cataracts 47,9%
  • Retinal diseases 13,5%
  • Glaucoma 12,3%
  • Other eye diseases 26,9%

- The ophthalmic industry and service provider revenue forecast 2020 (B2B)is reported with approx.  29,5 B $ Main business areas: Ophthalmic drugs (glaucoma etc.) with 40,5 B $, medical products/implants (IOL=Intraocular lenses) with  7,5 B $ and medical equipment for diagnosis and therapies with 7,0 B $ and other B2B areas with approx.. 1,5 B $. Major players are ALCON, Allergan, Bausch&Lomb, Topcon and Zeiss Meditec etc.

- Approx. 9,0% of the yearly  eye care revenue is spent for clinical research (e.g. clinical studies Phase I-IV) corresponding with approx. 6,9 B B US$.

Information sources:

  • WHO (World Health Organization)
  • ICO (International Council of Ophthalmology)
  • AAO (American Academy for Ophthalmology)
  • ASCRS (American Society for Cataract and Refractive Surgery)
  • ESCRS (European Society for Cataract and Refractive Surgery)
  • Publications of the ophthalmic industry (business reports etc.)

Further information: